Core View - Benchmark analyst Mark Zgutowicz has lowered the price target on Spotify (SPOT) to $760 from $860 while maintaining a Buy rating on the shares, indicating confidence in the company's future performance despite the price adjustment [1]. Group 1: Price Target and Rating - The price target for Spotify has been reduced to $760 from $860 [1]. - The firm continues to hold a Buy rating on Spotify shares [1]. Group 2: Market Position and Future Outlook - Spotify shares are currently about 32% below their 52-week high, suggesting potential for recovery [1]. - The firm anticipates multiple upcoming catalysts that could positively impact Spotify's performance [1]. - There is an expectation of better-than-expected incremental margin flow-through, which may lead to a re-rating of the company's valuation multiples [1]. - Spotify is highlighted as a 2026 Best Idea by the analyst, indicating strong long-term potential [1].

Group 1 - Benchmark raised the price target on XPO to $165 from $150 while maintaining a Buy rating on the shares [1] - The firm reduced Q4 and FY26 estimates due to quarter-to-date volumes running below normal seasonality and prior assumptions [1] - Benchmark views the near-term softness in XPO's performance as "cyclical rather than structural" [1] - XPO remains on Benchmark's Best Ideas list [1]

Group 1 - TD Cowen raised the price target on First Horizon (FHN) to $27 from $26 while maintaining a Hold rating on the shares [1] - The firm updated its model following solid Q4 results and guidance, highlighting improved lending with strong Commercial and Industrial (C&I) growth [1] - The 2026 guidance is favorable but likely requires significant contributions from countercyclical fees [1]

Group 1 - Wells Fargo raised the price target on BNY Mellon (BK) to $122 from $119 while maintaining an Equal Weight rating on the shares [1] - BNY Mellon beat Q4 2025 expectations on top line performance [1] - The 2026 guidance includes approximately 5% revenue growth and 3%-4% expense growth [1]

Group 1 - JPMorgan has lowered the price target on American Tower (AMT) to $245 from $250 while maintaining an Overweight rating on the shares [1] - The firm has reduced new leasing estimates for tower companies due to a more conservative approach influenced by the potential impact from EchoStar [1] - The industry outlook is described as "modest," but the EchoStar/Dish situation presents an overhang; however, potential deals could act as a positive catalyst for tower stocks [1]

Core Insights - CorMedix Therapeutics (NASDAQ: CRMD) is focused on developing therapeutic products for life-threatening diseases, with a new price target set at $16 by Truist Financial, indicating an 84.95% potential upside from its current trading price of $7.44 [1][6] Financial Performance - The company reported preliminary unaudited net revenue of approximately $127 million for Q4 2025 and $400 million for the full year 2025, reflecting its core business activities [3][6] - CorMedix expects its adjusted EBITDA for Q4 to be between $77 million and $81 million, indicating strong operational performance [4][6] - The company has unaudited cash and short-term investments of approximately $148 million, showcasing a solid financial position [4] Market Activity - CRMD's market capitalization is approximately $579.5 million, with a trading volume of 20.76 million shares [5] - The stock has experienced significant volatility, with a current price of $7.36, down 34.15% from a previous high, and has fluctuated between a low of $7.22 and a high of $9.36 on the day [2][5]

Benchmark lowered the firm’s price target on Comcast (CMCSA) to $44 from $46 and to formally reflect the consummation of the Versant (VSNT) spinoff and keeps a Buy rating on the shares. The firm, which lowered its 2026 and subsequent year revenue and EBITDA estimates to reflect the Versant spin, notes that its EBITDA estimates for 2026 and 2027 are consequently (3.5%) and (2.0%) below consensus as it appears based on FactSet consensus that only one other sell side firm has made this adjustment yet. Claim ...

Core Viewpoint - Morgan Stanley has increased the price target for Kimco Realty (KIM) to $23.50 from $22 while maintaining an Equal Weight rating on the shares following an update to its FY25 FFO per share estimate [1] Group 1 - Morgan Stanley raised the price target for Kimco Realty to $23.50 [1] - The previous price target was $22 [1] - The rating on the shares remains Equal Weight [1] Group 2 - The update was based on a revision of the FY25 FFO per share estimate [1]

Group 1 - Truist lowered the price target on MGM Resorts from $47 to $45 while maintaining a Buy rating on the shares [1] - The target cut is attributed to "more conservatism" regarding the company's growth inflection on the Las Vegas Strip [1] - November Strip gross gaming revenue decreased by 1% year-over-year, mainly due to lower table and baccarat win [1] Group 2 - Truist also reduced estimates for Caesars (CZR) alongside MGM, citing "soft" Strip RevPAR [1] - Despite the challenges on the Strip, both MGM and Caesars are viewed as "inexpensive" stocks [1] - The issues faced on the Strip are considered "well known" by the market [1]

Core Viewpoint - Morgan Stanley analyst Ronald Kamdem has raised the price target for FrontView REIT (FVR) to $14 from $13.50 while maintaining an Equal Weight rating on the shares after updating the firm's FY26 AFFO per share estimate [1] Summary by Category - **Price Target Adjustment** - The price target for FrontView REIT (FVR) has been increased to $14 from $13.50 [1] - **Rating** - The firm continues to hold an Equal Weight rating on the shares of FrontView REIT [1] - **Financial Estimate Update** - The update follows a revision of the firm's FY26 AFFO per share estimate [1]